Successful Haematopoietic Stem Cell Transplantation for LRBA Deficiency with Fludarabine, Treosulfan, and Thiotepa-Based Conditioning
Journal of Clinical Immunology · 2025
DOI: 10.1007/s10875-024-01770-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von Bella Shadur und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah University Medical Centre, Jerusalem, Israel. bella.shadur@gmail.com. Hauptthemen laut MEDLINE: Vidarabine, Hematopoietic Stem Cell Transplantation, Busulfan, Transplantation Conditioning. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of New South Wales.
Abstract (Originalsprache)
LRBA deficiency is an inborn error of immunity defined by autoimmunity, lymphoproliferation, recurrent infections, cytopenia, and inflammatory bowel disease. Despite recent advances in managing this disease with targeted biologic therapy, haematopoietic stem cell transplant (HSCT) remains the only cure. However, great variability exists between protocols used to transplant patients with LRBA deficiency. We describe a cohort of seven patients with LRBA deficiency who underwent HSCT using a myeloablative, reduced toxicity regime of fludarabine, treosulfan, and thiotepa at two transplantation centres from 2016 to 2019. Data were collected both retrospectively and prospectively, measuring time to engraftment, infectious complications, incidence of graft versus host disease, and post-transplantation chimerism. Six of seven patients survived transplantation, and four of six surviving patients achieving treatment-free survival. We thus recommend that HSCT with fludarabine, treosulfan, and thiotepa-based conditioning be considered in patients with LRBA deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah University Medical Centre, Jerusalem, Israel. bella.shadur@gmail.com.
- Garvan Institute of Medical Research, Sydney, Australia. bella.shadur@gmail.com.
- School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, NSW, Australia. bella.shadur@gmail.com.
- Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah University Medical Centre, Jerusalem, Israel.
- Department of General Paediatrics, Hadassah University Medical Centre, Jerusalem, Israel.
- Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Förderung
- University of New South Wales
Zitieren
APA
Shadur, B., NasserEddin, A., Zaidman, I., Schejter, Y. D., Even-Or, E., Berkun, Y., Meyts, I., Hmedat, H., Sulaiman, A., Tangye, S. G., & Stepensky, P. (2025). Successful Haematopoietic Stem Cell Transplantation for LRBA Deficiency with Fludarabine, Treosulfan, and Thiotepa-Based Conditioning. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01770-1
Vancouver
Shadur B, NasserEddin A, Zaidman I, Schejter YD, Even-Or E, Berkun Y, et al. Successful Haematopoietic Stem Cell Transplantation for LRBA Deficiency with Fludarabine, Treosulfan, and Thiotepa-Based Conditioning. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-024-01770-1
BibTeX
@article{Shadur2025,
author = {Shadur, Bella and NasserEddin, Adeeb and Zaidman, Irina and Schejter, Yael Dinur and Even-Or, Ehud and Berkun, Yackov and Meyts, Isabelle and Hmedat, Hatem and Sulaiman, Ashraf and Tangye, Stuart G and Stepensky, Polina},
title = {Successful Haematopoietic Stem Cell Transplantation for LRBA Deficiency with Fludarabine, Treosulfan, and Thiotepa-Based Conditioning},
journal = {Journal of Clinical Immunology},
year = {2025},
doi = {10.1007/s10875-024-01770-1}
}
EUVIMED